The role of high-dose methylprednisolone therapy in paroxysmal nocturnal hemoglobinuria

Erduran E., ASLAN Y., GEDIK Y., MOCAN H., OKTEN A. N.

TURKISH JOURNAL OF PEDIATRICS, cilt.37, sa.3, ss.283-287, 1995 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 3
  • Basım Tarihi: 1995
  • Dergi Adı: TURKISH JOURNAL OF PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.283-287
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder characterized by intermittent hemolytic anemia. High-dose methylprednisolone (HDMP) was administered in two patients, eight- and 16-year-old females, with PNH. This drug produced a dramatic improvement in the hemoglobin level, leukocyte and platelet counts. No side effect was observed in either patient during the treatment period. The patients were followed up on an outpatient basis for six and 16 months. In conclusion, HDMP therapy for PNH appears to be more effective and safe than previously reported therapies.